MediGene's RhuDex to undergo further safety tests
This article was originally published in Scrip
MediGene's rheumatoid arthritis candidate RhuDex will be examined in further laboratory tests to determine potential detrimental interactions between RhuDex and arteriosclerotic blood vessels. The studies are expected to be conducted in the first half of 2009 and will be a prerequisite for the further clinical development of the product.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.